Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide

Kavain

Status: Preclinical for isolated kavain (in-vitro and animal mechanistic data), , not approved for human use
Evidence: Not graded on a research bench yet

Kavain (kawain) is the principal kavalactone in kava (Piper methysticum) and the main compound behind kava's calming, anxiolytic effect. It positively modulates GABA-A receptors outside the benzodiazepine site and dampens voltage-gated Na+ and L-type Ca2+ channels.

Reviewed 30 October 2026

01Overview

What Kavain is

Sold as a research-use-only / supplement material in some regions; it carries a documented but idiosyncratic liver-injury risk. Research use only.

How it works

Kavain is the most abundant kavalactone in kava (Piper methysticum) and the main driver of the plant's calming activity. It is a research-use-only compound; the mechanisms below come from in-vitro and animal work on isolated kavain plus human trials of the parent kava extract.

Read the full mechanismShow less

GABA-A positive allosteric modulation: Kavain potentiates GABA-A receptors across many subunit combinations, enhancing GABA-evoked chloride current. This potentiation is NOT blocked by flumazenil and does not act through the classical benzodiazepine site - likely why kava produces calm without a typical benzodiazepine dependence profile [PMID:27332705]. Earlier radioligand work showed (+)-kavain enhances GABA-A binding without engaging the benzodiazepine site [PMID:9776662].
Voltage-gated Na+ channel blockade: Kavain non-competitively inhibits batrachotoxin binding to receptor site 2 of voltage-gated Na+ channels, reducing neuronal excitability [PMID:9690349].
Ca2+ and K+ channel effects: In hippocampal and dorsal-root-ganglion recordings, kavain shows weak Na+ antagonism, pronounced L-type Ca2+ channel antagonism, and positive modulation of the early K+ outward current - a pattern overlapping with mood-stabiliser drugs such as lamotrigine [PMID:11642654].
Broader CNS receptor activity: Kavain-containing kava extracts also interact in vitro with dopamine D2, opioid (mu/delta) and histamine receptors, which may shape the overall subjective profile [PMID:11458444].

Net effect: reduced neuronal excitability plus enhanced GABAergic tone, producing anxiolysis, mild sedation and muscle relaxation.

Benefits listed

Reduced anxiety and nervous tension - the parent standardized kava extract (of which kavain is the principal kavalactone) produced a moderate anxiolytic effect versus placebo in generalized anxiety disorder RCTs [PMID:23635869][PMID:19430766]
Physical and mental relaxation without the heavy sedation or dependence profile of benzodiazepines, since kavain modulates GABA-A outside the benzodiazepine site [PMID:27332705]
Calming and sleep-onset support, reported anecdotally with evening kava/kavain use (isolated-kavain benefit is extrapolated from extract data plus community use, not directly trialed)
Mild muscle relaxation and a soothing analgesic feel, consistent with kavain's effects on voltage-gated Na+ and L-type Ca2+ channels [PMID:9690349][PMID:11642654]

Show 1 moreShow less

Sociable, clear-headed calm frequently described in traditional and community use of kava beverages

What to expect

- Onset within roughly 15-45 minutes of an oral dose; effects typically last a few hours
- A calm, relaxed, often sociable and clear-headed feeling rather than heavy sedation at low doses
- Mild muscle relaxation and reduced physical tension
- Possible temporary tongue/mouth numbness with kava beverages (a local-anesthetic effect of kavalactones); less pronounced with capsules
- At higher doses: drowsiness and reduced coordination - do not drive or operate machinery
- No euphoric high; tolerance and next-day grogginess can appear with frequent use

Individual responses vary. Timeline based on commonly reported research observations.

02Research

Free with email

What the research shows

No research bench grades Kavain yet. Benches compare compounds people pair, with the evidence for each.

Key research findings

Isolated kavain has no dedicated human efficacy trials; the clinical evidence base is for standardized kava (Piper methysticum) extract, of which kavain is the major kavalactone.

A 6-week double-blind, placebo-controlled RCT in generalized anxiety disorder (120-240 mg kavalactones/day) found a significant, moderate reduction in Hamilton Anxiety scores versus placebo (Cohen d ~0.62), with 26% remission vs 6% on placebo and no group difference in liver-function tests over the short trial [PMID:23635869].
The KADSS crossover RCT using an aqueous kava extract (250 mg kavalactones/day) reported significant anxiolytic and antidepressant effects with no clinical hepatotoxicity at that dose and duration [PMID:19430766].
Mechanistic support: kavain potentiates GABA-A receptors outside the benzodiazepine site [PMID:27332705][PMID:9776662], blocks voltage-gated Na+ channels [PMID:9690349], and antagonises L-type Ca2+ channels with a mood-stabiliser-like profile [PMID:11642654]; kava extracts also engage D2/opioid/histamine receptors in vitro [PMID:11458444].
Safety literature: clinical and systematic reviews document idiosyncratic kava hepatotoxicity tied to dose, duration, raw-material quality and co-exposures [PMID:20720265][PMID:27092496][PMID:34307603]. Bottom line: a promising short-term anxiolytic signal for standardized kava extract; isolated-kavain efficacy and safety at supplement doses remain uncharacterised in humans. Research use only.

Safety and side effects

Commonly mild: GI upset/nausea, headache (more headaches were reported in the kava arm than placebo in a GAD trial [PMID:23635869]), daytime drowsiness, and mild dizziness. With chronic heavy use: 'kava dermopathy', a reversible dry, scaly, yellowed skin rash. Rare but serious: hepatotoxicity ranging from asymptomatic liver-enzyme elevation to acute liver injury and, rarely, liver failure requiring transplant [PMID:20720265][PMID:27092496][PMID:34307603]. Stop immediately and seek care for jaundice, dark urine, pale stools, right-upper-quadrant pain, nausea or unusual fatigue.

On PubMed

The search Kavain on PubMed.

Browse studies on PubMed

Unlock the research summary

Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

A summary of the key research
Safety and side effects
A link to the PubMed results

You also get the free peptide cheat sheet by email. Unsubscribe anytime.

Have an account? Sign in

03Safety

Kavain side effects and interactions

Side effects

Not in our record

Our record lists no side effects for Kavain. That means none are recorded here, not that there are none. The Research section has the written safety notes.

Who should not use it

Contraindications

Do not use with: existing liver disease or elevated liver enzymes; alcohol; other hepatotoxic drugs or supplements; pregnancy or breastfeeding. Avoid before driving or operating machinery, and before surgery (CNS-depressant and possible additive effects with anesthesia). Caution or avoid with benzodiazepines, barbiturates, opioids, Z-drugs and other CNS depressants (additive sedation). Because kava/kavain has dopamine D2 antagonist activity [PMID:11458444], avoid in Parkinson's disease or with dopaminergic therapy. Not for use under 18. Discuss with a clinician before use if you take any prescription medication, especially drugs metabolized by liver CYP450 enzymes.

Interactions

6 pairings in our record: 6 not rated.

Not rated

Alcohol - additive CNS depression and markedly increased hepatotoxicity risk; do not combine
Not rated

Benzodiazepines, barbiturates, Z-drugs, opioids and other sedatives - additive sedation and CNS depression
Not rated

Hepatotoxic drugs and supplements (e.g., excess acetaminophen, certain statins, other herb-induced-liver-injury agents) - compounded liver risk [PMID:34307603]
Not rated

Dopaminergic / anti-Parkinson drugs - kava's D2 antagonism may oppose them and can provoke extrapyramidal effects [PMID:11458444]
Not rated

Liver CYP450 substrates - kavalactones inhibit several CYP enzymes in vitro, which could raise blood levels of co-administered medications; check with a pharmacist
Not rated

Anesthetics - potentiation of anesthetic/sedative effect; stop before scheduled surgery

This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

Need bloodwork before starting?

Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.

Order Bloodwork

04Dosing

Free with email

Kavain dosage and protocols

Dose range: 50-250 mg
Dosing: 1-2 times daily, as needed; not intended for continuous long-term daily use

Dosing summary

Dose: 50-250 mg
Frequency: 1-2 times daily, as needed; not intended for continuous long-term daily use
Duration: Time-limited - controlled kava-anxiety trials ran ~3-6 weeks [PMID:19430766][PMID:23635869]. Take regular breaks and avoid indefinite daily dosing; longer duration is a documented hepatotoxicity risk factor [PMID:20720265].

Protocols

Beginner protocol

RUO / educational only - not medical advice. Note that the well-studied clinical product is standardized WHOLE kava root extract, not the isolated single molecule; isolated-kavain dosing below is extrapolated and not clinically validated.

Starter approach (isolated kavain): 50 mg once daily, taken with food, in the evening or ~30-60 minutes before a known stressor. Assess tolerance and liver comfort over the first 1-2 weeks. Standardized kava-extract trials delivered 120-250 mg total kavalactones/day [PMID:23635869][PMID:19430766]; a 50 mg kavain dose sits at the low end of that kavalactone load.

Hard rules from day one: no alcohol, no other hepatotoxic drugs or supplements, and a baseline liver-function panel (ALT/AST) is wise given documented kava hepatotoxicity [PMID:20720265][PMID:27092496]. Do not drive until you know how it affects you.

Intermediate protocol

For those already tolerating kavain: 50-100 mg, 1-2x daily as needed (e.g., morning and evening), staying at or below roughly 250 mg kavalactone-equivalent per day to remain within the range used in controlled kava trials [PMID:23635869]. Prefer aqueous/traditional-style or high-quality material; poor raw-material quality is a suspected contributor to liver injury [PMID:20720265].

Keep continuous use time-limited (the GAD RCT ran 6 weeks [PMID:23635869]) and take periodic breaks. Re-check ALT/AST if using regularly beyond a few weeks, and stop immediately at any sign of liver trouble (dark urine, jaundice, right-upper-quadrant pain, unusual fatigue).

Advanced protocol

Experienced users sometimes push total daily kavalactone intake toward 300-500 mg (from kavain plus whole-kava sources) for acute situational anxiety, but there is NO controlled human evidence that isolated kavain is safe or effective at these doses, and higher dose and longer duration are documented risk factors for kava hepatotoxicity [PMID:20720265]. This is not a recommendation.

If used at all: single-day or short-run situational dosing rather than chronic daily use; strict abstinence from alcohol and other liver-stressing agents; and lab monitoring. Chronic heavy kava use is also associated with a reversible scaly skin rash (kava dermopathy). There is no established benefit to daily high-dose use, and the risk/benefit balance worsens the higher and longer you go.

Additional dosage notes

Isolated kavain is a single kavalactone; the human evidence base is for whole standardized kava extract standardized to total kavalactones, not the pure molecule. Doses are best expressed as kavalactone-equivalents and kept within the 120-250 mg/day range used in trials [PMID:23635869][PMID:19430766]. Take with food, avoid alcohol entirely, and favor high-quality/aqueous-style material - poor raw-material quality is a suspected contributor to kava liver injury [PMID:20720265]. Baseline and periodic liver-function testing is prudent.

Unlock the dosing protocols

Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

Dose, how often and how long
Beginner, intermediate and advanced protocols
Additional dosage notes

You also get the free peptide cheat sheet by email. Unsubscribe anytime.

Have an account? Sign in

05Prices

Kavain prices

No listings

We do not track a vendor for Kavain yet, so this page states no price.

06Chemistry

Chemistry and structure

Molecular mass: 230.26 g/mol (C14H14O3; PubChem CID 837). Naturally occurring form is the (+)-enantiomer.
Half-life: Not firmly established for isolated kavain in humans. Kavalactones are lipophilic and rapidly absorbed, with subjective effects generally lasting a few hours. Limited pharmacokinetic data preclude a precise elimination half-life.

08Questions

Frequently asked questions

Is kavain the same thing as kava?

No. Kava is the whole Piper methysticum root and its extract, which contains at least six major kavalactones. Kavain is the single most abundant of those kavalactones and the main driver of kava's calming effect. Most human trials used standardized whole extract, not isolated kavain [PMID:23635869][PMID:19430766].

How does kavain calm anxiety?

It positively modulates GABA-A receptors without acting on the benzodiazepine site [PMID:27332705], and it blunts neuronal excitability by inhibiting voltage-gated Na+ channels and L-type Ca2+ channels [PMID:9690349][PMID:11642654].

Is kavain addictive like benzodiazepines?

Kavain works outside the benzodiazepine site and has a low physical-dependence profile compared with benzodiazepines [PMID:27332705], but it can still impair coordination and cause next-day grogginess with frequent use. It is not a benzodiazepine substitute and should not be combined with one.

Is kavain safe for the liver?

Kava/kavain carries a real but idiosyncratic hepatotoxicity risk. Short controlled trials of standardized extract showed no liver-enzyme changes [PMID:23635869], but clinical and systematic reviews document cases of serious liver injury linked to high dose, long duration, poor material quality, alcohol and co-medication [PMID:20720265][PMID:27092496][PMID:34307603]. Avoid alcohol, get baseline and periodic liver labs, and stop at any sign of liver trouble.

How much kavain do people take?

Isolated-kavain supplements are typically 50-100 mg per dose; controlled kava trials delivered 120-250 mg total kavalactones per day [PMID:23635869][PMID:19430766]. There is no validated dose for isolated kavain - start low, keep it time-limited, and do not exceed the kavalactone range used in trials without medical guidance.

Can I take kavain with my medications?

Be cautious. Avoid alcohol and other CNS depressants (benzodiazepines, opioids, Z-drugs), avoid combining with hepatotoxic drugs, and avoid with dopaminergic/Parkinson's medications due to kava's D2 antagonism [PMID:11458444]. Kavalactones can also inhibit liver CYP450 enzymes and raise levels of other drugs - check with a pharmacist or physician first.

Is kavain legal or approved?

It is not FDA-approved as a drug. It is sold as a supplement/RUO material in some regions, while whole-kava products are banned or restricted in several countries over liver concerns. Isolated D,L-kavain was once a prescription anxiolytic in Germany and was later withdrawn. Research use only.

Price check

No vendor listings yet

We do not track a vendor for Kavain yet.

Compare other compounds

Spec sheet

Kavain

Half-life: Not firmly established for isolated kavain in humans
Molecular weight: 230.26 g/mol (C14H14O3
Also known as: 1 name

Charisma

Articles on Kavain

Free 2026 Peptide Cheat Sheet (PDF)

38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

Download Free